ICIs directed against CTLA-4 (ipilimumab), PD-1 (pembrolizumab and nivolumab), or PD-L1 have transformed the treatment landscape of tumors, such as melanoma and non–small cell lung cancer, where tumor-infiltrating lymphocytes are abundant. Here, CD274 is linked to lung cancer.